To our knowledge, this study is the first to have explored respondents’ tolerance for certain safety risks associated with HER2-targeted treatment in exchange for slowing disease progression, as well as the first study to evaluate preferences for breast cancer treatments across the US, UK, and Japan [16]. Here, ERBB2 is linked to breast carcinoma.